The information contained on this page is provided by the respective companies noted. It does not necessarily reflect the Society’s viewpoint and may redirect the user to a third-party site. ASE has posted this content on ContrastZone as a convenient way to access multiple pieces of information in one place, in alignment with our Society’s goal to provide resources and education to enhance the access to and quality in cardiovascular ultrasound.
January 2017: The FDA removes the contraindication for use of Bracco Diagnostics Inc.’s LUMASON® (sulfur hexafluoride lipid-type A microspheres) for injectable suspension, for intravenous use or intravesical use, in patients with cardiac shunts
March 2016: LUMASON is now FDA approved for use in ultrasonography of the liver
Bracco Diagnostics Inc., the U.S. subsidiary of Bracco Imaging S.p.A., one of the world’s leading companies in the diagnostic imaging business, announced today that LUMASON is now approved for use in ultrasonography of the liver for characterization of focal liver lesions in adult and pediatric patients.
Lumason Formulary Kit: includes Lumason Product Monograph, Safety Data Sheet, FDA Approval Letter, and Prescribing Information
Lumason Brochure: overview of product
Optison Case Study Video (it is highly suggested that Google Chrome is used with this link)
Lantheus Medical Imaging
DEFINITY® Vial for (Perflutren Lipid Microsphere) Injectable Suspension
Lantheus Medical Imaging, Inc.